For example, the interaction between TRAF2 and LIRB3 is depleted by overactivated NF-κB activation, and the signaling axis is antagonized to inhibit the progression of AML, making targeting LILRB3 a potential intervention option [37]. The gene discussed is TRAF2; the disease is acute myeloid leukemia.